The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

about

Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model.Activation of multiple angiogenic signaling pathways in hemangiopericytoma.

P2860

Q48265668-A0CDB7CE-9310-4759-B1FE-CEA968E3EB80 Q48854018-7EF1F2F8-836B-452A-A1BA-23F27671C048

P2860

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

Item

http://www.wikidata.org/entity/Q48213840

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

@en

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

@nl

type

Item

label

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

@en

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

@nl

prefLabel

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

@en

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

@nl

P1476

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

@en

P2093

Alba A Brandes

http://www.w3.org/2001/XMLSchema#string

P2860

Practical management of bevacizumab-related toxicities in glioblastoma

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

P304

117-119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2217/CNS.15.7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Enrico Franceschi

P577

2015-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25906382

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

6088337

http://www.w3.org/2001/XMLSchema#string

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

about

P2860

P2860

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932